Patient | Age | Sex | Diagnosis | Spleen | Other | Treatment | N(/mm3) | Infection | Disease duration (y) | Status |
---|---|---|---|---|---|---|---|---|---|---|
M, male; F, female; E, enlarged; NE, not enlarged; N, neutrophils; A, alive; D, deceased; PRED, prednisone; ANA, antinuclear antibodies; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs. | ||||||||||
Patients diagnosed with FS or PFS fulfilled ACR criteria for definite or probable RA.22 T-LGLD diagnosis assigned clinically plus typical findings on blood smear or detection of increased CD57+ or CD16+ cells by FACS analysis. | ||||||||||
*T cell lymphoma developed six months before death. | ||||||||||
1 | 70 | M | FS/T-LGLD | E | Fever | MTX | 828–1000 | Mild | 8 | A |
ANA weak+ | PRED | |||||||||
NSAID | ||||||||||
2 | 63 | F | T-LGLD | NE | Pleuropericarditis, cerebral ischaemia | None | 400–860 | Mild | 5 | A |
NSAID | ||||||||||
3 | 50 | M | T-LGLD | E | Psoriasis, haemolytic anaemia | NSAID | 290–500 | Mild | 5 | A |
4 | 47 | M | T-LGLD | E | Pleuropericarditis, cerebral ischaemia, ANA weak+ lymphoma* | MTX | 50–1000 | Mild | 13 | D |
PRED | ||||||||||
NSAID | ||||||||||
5 | 59 | M | PFS/T-LGLD | E | PRED | 70–100 | Severe | 11 | D | |
NSAID | ||||||||||
6 | 63 | M | FS/T-LGLD | E | MTX | 100–500 | Severe | 7 | D | |
PRED | ||||||||||
NSAID |